Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
11%
Ph phase_2
3
33%
Ph not_applicable
5
56%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
3(33.3%)
N/ANon-phased studies
5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(7)
Completed(1)
Terminated(1)

Detailed Status

Enrolling by invitation3
Recruiting3
Not yet recruiting1
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (11.1%)
Phase 23 (33.3%)
N/A5 (55.6%)

Trials by Status

not_yet_recruiting111%
enrolling_by_invitation333%
completed111%
recruiting333%
withdrawn111%

Recent Activity

3 active trials
Showing 5 of 9
enrolling_by_invitationphase_1

TSPO Endothelial - EMPATHY

NCT07697183
recruitingphase_2

Role of a Mitochondrial Receptor in Blood Sugar Regulation

NCT07682233
enrolling_by_invitationnot_applicable

TSPO Occupancy in the Human Lung

NCT07362290
not_yet_recruitingnot_applicable

Endothelial Cell Activation and Total Pulmonary Resistance in PAH

NCT06035861
enrolling_by_invitationphase_2

TSPO Modulation in AD

NCT07191821
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07697183Phase 1

TSPO Endothelial - EMPATHY

Enrolling By Invitation
NCT07682233Phase 2

Role of a Mitochondrial Receptor in Blood Sugar Regulation

Recruiting
NCT07362290Not Applicable

TSPO Occupancy in the Human Lung

Enrolling By Invitation
NCT06035861Not Applicable

Endothelial Cell Activation and Total Pulmonary Resistance in PAH

Not Yet Recruiting
NCT07191821Phase 2

TSPO Modulation in AD

Enrolling By Invitation
NCT03850301Not Applicable

Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target

Recruiting
NCT06643013Not Applicable

Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease

Recruiting
NCT02086240Not Applicable

Reproducibility of the 11C-PBR28 PET Signal

Withdrawn
NCT00108836Phase 2

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9